Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1864
- Registration Number
- NCT02607865
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT02577003
Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 21
- Registration Number
- NCT02576288
- Locations
- 🇺🇸
University of Southern California Health Sciences Campus, Los Angeles, California, United States
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 141
- Registration Number
- NCT02577016
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT02564211
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 202
- Registration Number
- NCT02556918
- Locations
- 🇺🇸
Emory Univeristy Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Sitagliptin Therapy and Kinetics of Inflammatory Markers
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Laval University
- Target Recruit Count
- 20
- Registration Number
- NCT02536248
- Locations
- 🇨🇦
Laval University, Quebec City, Quebec, Canada
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 614
- Registration Number
- NCT02532855
Sitagliptin for Reducing Inflammation and Immune Activation
- Conditions
- Interventions
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2018-06-18
- Target Recruit Count
- 90
- Registration Number
- NCT02513771
- Locations
- 🇺🇸
UCLA CARE Center CRS (601), Los Angeles, California, United States
🇺🇸Case CRS (2501), Cleveland, Ohio, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, United States
Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02512523
- Locations
- 🇰🇷
HANDOK Inc., Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.